National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 3 of 1991)

Overview

The National Health Act 1953 was enacted by the Australian Parliament to provide a framework for ensuring the health and well-being of Australians through a range of mechanisms, including the Pharmaceutical Benefits Scheme. The Act was designed to address the need for a coordinated approach to health care funding and provision across the country, aiming to make essential medications more affordable and accessible to the public. The Pharmaceutical Benefits Declaration under subsection 85(2AA), dated 22 March 1991 and made by Margaret Nona Ford, Principal Advisor of the Health Care Access Division in the Department of Community Services and Health, serves to remove certain drugs and medicinal preparations from the scope of Part VII of the Act, thereby altering their eligibility under the Pharmaceutical Benefits Scheme. This specific declaration, which came into operation on 1 April 1991, was made following advice from the Pharmaceutical Benefits Advisory Committee, reflecting the policy objective of periodically reviewing and adjusting the list of subsidised medications to ensure optimal use of public health resources.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85(2AA) of the National Health Act 1953 applies to the specified drugs and medicinal preparations listed in the Schedule, which cease to be subject to Part VII of the Act. This Act pertains to the regulation and administration of pharmaceutical benefits within the Commonwealth of Australia. The declaration impacts the pharmaceutical industry by removing certain drugs and medicinal preparations from the scope of the Pharmaceutical Benefits Scheme, thereby affecting their eligibility for subsidies and listings on the Schedule of Pharmaceutical Benefits. The geographic reach of this legislation is national, as it is enacted under the authority of the Commonwealth of Australia and applies across the country. There are no stated exclusions or exemptions in this particular declaration, and the application is direct and straightforward without reliance on subordinate instruments for extension or restriction. The declaration came into effect on 1 April 1991, as specified, and is intended to update the list of pharmaceutical benefits in line with current health care practices and recommendations from the Pharmaceutical Benefits Advisory Committee.

Key Provisions

The main operative sections of the Pharmaceutical Benefits Declaration under subsection 85(2AA) of the National Health Act 1953 (subsections 85(2AA) and 85(2AB)) require the Minister for Health to obtain advice from the Pharmaceutical Benefits Advisory Committee before making a declaration that removes certain drugs and medicinal preparations from the Pharmaceutical Benefits Scheme (PBS). This Declaration, effective from 1 April 1991, specifies that the drugs and preparations listed in the Schedule will no longer be covered by Part VII of the National Health Act 1953. The Act imposes several obligations on the parties it governs. Firstly, the Minister, acting through the Delegate, must consult with the Pharmaceutical Benefits Advisory Committee and consider their advice before making a decision to remove a drug from the PBS. This ensures that the decision is based on expert medical advice and comprehensive consideration of the implications of such a change. Furthermore, the Declaration must be made in accordance with the legislative requirements, and the specified drugs and preparations must be accurately listed in the Schedule. Failure to comply with the provisions of the Act can result in significant consequences. Although the legislation does not explicitly outline specific offences or penalties for breaches, non-compliance with the Act’s requirements to consult with the Pharmaceutical Benefits Advisory Committee and make a proper declaration could potentially lead to legal challenges or administrative penalties. Additionally, any improper removal of drugs from the PBS without following the mandated process could result in legal action being taken against the responsible authorities, with potential implications for the affected parties, including patients and healthcare providers. The maximum penalties for such breaches, however, are not specified within the text of the Declaration itself.